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Abstract
Introduction: Chest pain with ST-segment elevation is a rare clinical problem during dobutamine
stress testing. Although beta-agonists treatment prior to dobutamine stress testing has been shown
to reduce the duration and amount of dobutamine infusion and atropine requirement, there is
insufficient information about potential complications of this pharmacologic combination.
Case presentation: We present a 67-year-old patient with dobutamine stress testing -induced
chest pain and ST elevation who received albuterol for clinical treatment of bronchospastic disease
prior to the test. She developed persistent chest pain and ST elevation despite medical management.
Urgent cardiac catheterization showed no significant obstructive coronary artery disease. Thus
coronary artery spasm was likely responsible for the chest pain and electrocardiogram abnormality in
our patient as a result of b-agonist and dobutamine combination.
Conclusions: Beta-agonists pre-treatment with dobutamine stress testing may induce coronary
spasm in association with chest pain and ST elevation. Clinicians and nuclear cardiologist should be
aware of this potential side effect of b-agonists treatment with dobutamine stress testing, particularly
since dobutamine stress testing in nuclear cardiology is done in patient with chronic obstructive lung
disease.
Introduction
Dobutamine infusion in combination with radionuclide
myocardial perfusion imaging is an alternative pharmaco-
logical stress test for detection of myocardial ischemia in
patient who is not able to tolerate dipyridamole or
adenosine infusion. It is commonly used in patients with
chronic obstructive pulmonary disease (COPD). As a
catecholamine with predominant b1 receptor against,
dobutamine increases heart rate, systolic blood pressure
and myocardial contractility. Consequently, myocardial
oxygen demand increases. Although its hemodynamic
effect is similar to physical exercise, dobutamine stress
test (DST) is not a substitute for exercise stress test. Serious
side effects may occur during DST including myocardial
infarction, ventricular arrhythmia, hypotension and pro-
longed ischemia [1-3]. However ST-segment elevation
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(page number not for citation purposes)(STSE) with chest pain is a rare event in DST with
myocardial perfusion imaging.
Numerous studies have demonstrated that DST in
association with radionuclide or echocardiographic ima-
ging is sensitive and specific diagnostic test for coronary
artery disease. In order to maintain sensitivity of DST, it is
important to reach target heart rate during the test.
Atropine is usually combined with dobutamine infusion
to increase heart rate. It has been demonstrated that
b-agonists treatment shortly prior to DST reduced amounts
and duration of dobutamine infusion as well as require-
ment of atropine [4]. However it is not clear whether the
incidence of ST-segment elevation with chest pain
increases with the b-agonist and dobutamine combina-
tion. This is particularly important for the patients who
undergo DST with nuclear imaging since the number of
studies is limited and this patient population has multiple
co-morbidities.
Case presentation
A67-year-oldCaucasianfemalewithsevereCOPDwhowas
receiving continuous oxygen treatment in addition
to multiple bronchodilator and ant-inflammatory
medications including fluticasone/salmeterol (Advair),
tiotropium-bromide (Spiriva), ipratropium-bromide/
albuterol-sulfate (DuoNeb) and budesonide (Pulmicort),
presentedtothehospitalwithsuddenonsetsubsternalchest
pressure at rest which resolved spontaneously. She has no
historyofcoronaryarterydisease,butlimitedcardiovascular
risk factors including age and hypertension. Her physical
examination was unremarkable with the exception of
elevated blood pressure (158/92 mmHg). Serial electro-
cardiogram and cardiac enzymes during hospital course
were within normal limits. For that reason, DST was
scheduled. The patient received albuterol inhaler treatment
30 minutes prior to DST in addition to her scheduled
bronchodilators as above. She underwent pharmacological
stress test with dobutamine infusion at a maximum rate of
40mcg/kg/min,a total dose of 28mg, andatropine 0.2 mg.
She reached to target heart rate with dobutamine/atropine
combination. Blood pressure response was normal. During
recovery the patient developed severe substernal chest pain
that was similar to her prior pain and radiated to jaw. She
appeared diaphoretic, pale and sick. Concurrent electro-
cardiogram showed 1.5 mm STSE in lead II, III, aVF, V3, V4
and V5 (Figure 1A & B). There was only minimal
improvement of chest pain with sublingual nitroglycerine.
ST-segment remained elevated. Thus the patient underwent
urgent cardiac catheterization. Coronary angiogram
revealed no obstructive epicardial coronary artery disease
(Figure 2A & B). Chest pain resolved during catheterization
while she was receiving nitroglycerine infusion and
morphine. Thus our patient likely manifested coronary
spasm with chest pain and STSE in the setting of albuterol
and dobutamine combination. There was no evidence of
myocardial necrosis based on biomarkers. The patient’s
hospital course was uncomplicated. She remained chest
pain free with medical management including long acting
nitroglycerine.
Figure 1. Electrocardiogram at baseline (A) and recovery
phase of dobutamine stress test in association with chest pain
(B), which shows ST-segment elevation in lead II, III, aVF,
V3, V4 and V5.
Figure 2. Coronary angiograms demonstrate no obstructive
disease at left (A) and right (B) coronary artery systems.
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Pre-treatment with b-agonists in DST reduces the time of
the test and the use of atropine in addition to requiring
lesser amount of dobutamine infusion. However it is not
known whether b-agonists may have additive effect on
inducing coronary spasm and related STSE with angina
during DST. Physiologic response to dobutamine and
b-agonists on circulatory system are similar that may
enhance overall effects of each other.
STSE during stress test occurs in the presence of myocardial
ischemia, coronary spasm or left ventricular dysfunction. It
is rare clinical problem in patients without previous infract
or coronary artery disease and associated with coronary
spasm or non-occlusive coronary lesion [2,5]. Typically
STSE secondary to coronary spasm occurs in recovery
phase of DST with no response to b-blocker [2,4-6].
The mechanism of dobutamine induced vasospasm with
or without b-agonists is complex. Dobutamine primarily
stimulates cardiomyocyte sarcolemma b1-adrenergic
receptors, but also has effect on b2- and a1-receptors.
Increase in myocardial oxygen demand and coronary flow
causes a-adrenergic mediated vasoconstriction that has
been observed during exercise. In fact exercise-induced
coronary spasm is a result of a1 receptor stimulation.
Higher doses of dobutamine, as in DST, generate more a1-
adrenergic effect that may induce coronary spasm,
particularly in the presence of endothelial dysfunction
[6]. Moreover, dobutamine-induced coronary vasocon-
striction ismediated through postjunctional a2-adrenergic
receptors [7].
b-agonists cause cardiovascular side effects including
angina, tachyarrhythmias, hypertension and myocardial
injury by increasing myocardial oxygen consumption.
Albuterol activates b2-adrenergic receptors particularly
in coronary resistant vessels that are partially mediated
by the endothelium at the microcirculatory level. Endothe-
lial function plays important role in b2-agonist effect on
vascular tone. Intracoronary infusion of salbutamol
induces vasoconstriction in stenotic coronary arteries
without increase in heart rate and blood pressure [8].
Underlying endothelial dysfunction was likely a reason for
our patient to develop coronary spasm in response to
albuterol and dobutamine combination since she had no
obstructive coronary disease.
Conclusions
Albuterol pre-treatment with DST may induce coronary
spasm in association with chest pain and STSE. This
clinical condition may lead to invasive procedures like
cardiac catheterization and possible complications.
Although the true incidence of coronary vasospasm with
STSE during DST with albuterol pre-treatment is not
known, nuclear cardiologist must be aware of this
potentially life threatening complication of this non-
invasive diagnostic test. Coronary spasm should be
considered in all patients with STSE and chest pain during
DST, particularly following b-agonist treatment. The safety
of this combination must be re-examined. Thus, the
patients should not be subjected to the DST if they are
treated with b-agonist before the test.
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